Although patients may regain nearly two-thirds of their lost weight on GLP-1 RAs after cessation of the drug16, this early positive reinforcement may serve as an incentive to pursue a long-term, multipronged approach to combat obesity. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.